SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-017492
Filing Date
2023-05-15
Accepted
2023-05-15 17:00:53
Documents
61
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 779973
2 ex31-1.htm EX-31.1 20716
3 ex31-2.htm EX-31.2 20347
4 ex32-1.htm EX-32.1 6229
5 ex32-2.htm EX-3.2 6054
  Complete submission text file 0001493152-23-017492.txt   4721469

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE gtbp-20230331.xsd EX-101.SCH 39284
7 XBRL CALCULATION FILE gtbp-20230331_cal.xml EX-101.CAL 41104
8 XBRL DEFINITION FILE gtbp-20230331_def.xml EX-101.DEF 173945
9 XBRL LABEL FILE gtbp-20230331_lab.xml EX-101.LAB 327684
10 XBRL PRESENTATION FILE gtbp-20230331_pre.xml EX-101.PRE 268075
55 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 661824
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40023 | Film No.: 23923951
SIC: 2834 Pharmaceutical Preparations